Bio-Techne Corp. (TECH)

Name: Bio-Techne Corp. (TECH): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Bio-Techne Corp. (TECH) reported revenue of $321 million for Q4 FY2026, the quarter ended 30 June 2026, up 1.3% on the same quarter a year earlier. Net income was $55 million, and diluted earnings per share $0.36. The figures are the company's own, from the 10-K it filed with the SEC on 24 August 2026.

Revenue$321 millionup 1.3%

Net income$55 million

Diluted EPS$0.36

QuarterQ4 FY2026ended 30 June 2026

Ratios

From the filings

ROE8.6%

ROCE10.9%

Operating margin20.7%

Net margin15.0%

FCF margin21.7%

Interest cover26.16

Debt to equity0.09

Cash conversion1.61

Share count, 1 year0.7%

Sales CAGR, 3 years2.2%

Profit CAGR, 3 years-13.9%

EPS, TTM$1.16

At the close of 21 September 2026

Price$72.47

Market cap$11.3 billion

Stock P/E62.47

Price to book5.37

EV / EBITDA32.20

Dividend yield0.4%

Market cap / sales9.31

52-week high$72.48

52-week low$43.30

Price, 1 year36.4%

Price CAGR, 3 years1.5%

Price CAGR, 5 years-11.5%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on the one borrowings figure Bio-Techne Corp. files, which has finance leases inside it; operating leases are a separate line. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on TECH

Filings	19 in twelve months: 8 current reports (8-K), about 6 other events; 4 results of operations; 2 officer or director change; 1 material agreement; 1 regulation fd disclosure
Planned insider sales	2 Form 144 notices in twelve months, $437,209; latest 8 May 2026
Options tape	put/call 0.05 by open interest on 23 September 2026; the straddle prices a 4.2% move to 16 October 2026
Holders	10 of the followed funds hold it; largest FMR LLC; 5 Schedule 13D or 13G filings in twelve months
Insider trading	2 sales and 0 purchases on Form 4 in twelve months
Congress	2 House trades disclosed in six months
Short interest	5.9 million shares short, 2.50 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026	Q4 FY2026 *
Revenue	277	273	303	306	289	297	316	317	287	296	311	321
Cost of revenue	91.7	96.0	98.8	103	106	103	102	118	98.4	105	103	110
Gross profit	185	177	205	203	183	194	215	199	188	191	208	211
Gross margin	67%	65%	67%	66%	63%	65%	68%	63%	66%	65%	67%	66%
R&D	24.0	22.9	25.8	24.0	23.9	25.0	24.6	26.0	24.2	23.1	23.5	23.9
SG&A	105	116	112	134	119	121	151	197	116	114	109	113
Operating income	55.9	38.0	67.0	45.8	40.0	47.4	38.7	-23.9	47.7	54.5	75.5	74.3
Operating margin	20%	14%	22%	15%	14%	16%	12%	-8%	17%	18%	24%	23%
Interest expense	4.9	4.3	4.0	2.5	2.2	2.1	2.0	2.2	2.9	2.2	2.4	2.1
Pre-tax income	49.6	33.4	61.1	41.7	40.2	42.9	38.3	-22.9	48.0	50.8	71.2	70.7
Tax rate	-3%	18%	20%	3%	16%	19%	41%	n/a	20%	25%	28%	23%
Net income	51.0	27.5	49.1	40.6	33.6	34.9	22.6	-17.7	38.2	38.0	51.0	54.6
Net margin	18%	10%	16%	13%	12%	12%	7%	-6%	13%	13%	16%	17%
Diluted EPS	$0.31	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14	-$0.11	$0.24	$0.24	$0.32	$0.36
Operating cash flow	59.4	83.1	81.0	75.5	63.9	84.3	41.1	98.2	27.6	82.4	86.7	95.4
Capital expenditure	13.6	14.9	16.4	18.0	9.2	6.8	10.1	4.9	5.4	5.9	9.1	8.5
Free cash flow	45.8	68.3	64.5	57.5	54.7	77.5	31.0	93.3	22.2	76.5	77.6	86.9
Buybacks	n/a	n/a	0.0	n/a	n/a	n/a	100	n/a	0.0	0.0	0.0	41.7
Dividends paid	12.7	12.6	12.6	12.6	12.7	12.7	12.6	12.4	12.4	12.5	12.5	12.5
Shares outstanding	158m	157m	158m	158m	159m	158m	157m	155m	156m	156m	157m	156m
Filing	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	TTM
Revenue	452	499	563	643	714	739	931	1,106	1,137	1,159	1,220	1,215	1,215
Cost of revenue	145	162	188	211	241	255	298	349	367	389	429	416	416
Gross profit	307	337	375	432	473	483	633	756	770	770	790	799	799
Gross margin	67.9%	67.5%	66.5%	67.2%	66.3%	65.4%	68.0%	68.4%	67.7%	66.4%	64.8%	65.8%	65.8%
Research and development	40.9	45.2	53.5	55.3	62.4	65.2	70.6	87.1	92.5	96.7	99.5	94.8	94.8
Selling, general and administrative	119	141	200	241	264	261	325	373	378	466	589	452	452
Operating income	147	151	121	136	147	157	237	297	299	207	102	252	252
Operating margin	32.5%	30.2%	21.4%	21.2%	20.5%	21.3%	25.5%	26.8%	26.3%	17.8%	8.4%	20.7%	20.7%
Interest expense	1.5	1.7	7.4	10.2	21.7	19.2	14.0	11.3	11.2	15.7	8.5	9.6	9.6
Pre-tax income	154	147	112	126	112	276	148	301	339	186	98.5	241	241
Income tax	46.4	43.0	35.9	-0.2	15.9	47.2	8.6	38.3	53.2	17.6	25.1	58.8	58.8
Effective tax rate	30.1%	29.2%	32.0%	-0.2%	14.2%	17.1%	5.8%	12.7%	15.7%	9.5%	25.5%	24.4%	24.4%
Net income	108	104	76.1	126	96.1	229	140	272	285	168	73.4	182	182
Net margin	23.8%	20.9%	13.5%	19.6%	13.5%	31.0%	15.1%	24.6%	25.1%	14.5%	6.0%	15.0%	15.0%
Diluted EPS	$2.89	$2.80	$2.03	$3.31	$2.47	$5.82	$3.47	$6.63	$1.76	$1.05	$0.46	$1.16	$1.16
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	TTM
Operating cash flow	n/a	144	144	170	182	205	352	325	254	299	288	292	292
Capital expenditure	19.9	16.9	15.2	20.9	25.4	51.7	44.3	44.9	38.2	62.9	31.0	28.9	28.9
Free cash flow	n/a	127	129	149	156	153	308	280	216	236	257	263	263
Free cash flow margin	n/a	25.5%	22.8%	23.2%	21.9%	20.8%	33.1%	25.4%	19.0%	20.4%	21.0%	21.7%	21.7%
Depreciation and amortisation	37.2	42.8	60.0	64.5	78.2	82.7	87.7	101	107	112	110	97.4	97.4
Share-based compensation	6.0	9.4	14.6	28.2	32.3	32.4	49.0	42.2	39.2	38.0	40.8	41.4	41.4
Buybacks	0.0	n/a	n/a	0.0	15.4	50.1	43.2	161	19.6	80.0	276	41.7	41.7
Dividends paid	47.1	47.6	47.3	48.0	48.4	48.9	49.6	50.2	50.3	50.4	50.4	49.9	49.9
Dividend per share	$1.27	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$0.32	$0.32	$0.32	$0.32	n/a
Diluted shares, weighted	37m	37m	38m	38m	39m	39m	40m	41m	162m	161m	160m	157m	157m
Shares outstanding at period end	37m	37m	37m	38m	38m	38m	39m	39m	158m	158m	155m	156m	156m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	TTM
Total assets	1,063	1,130	1,558	1,593	1,884	2,028	2,263	2,295	2,639	2,704	2,558	2,587	2,587
Cash and equivalents	54.5	64.2	91.6	122	101	147	199	173	181	152	162	265	265
Receivables	70.0	93.4	117	120	137	123	145	195	218	241	207	217	217
Inventory	49.6	57.1	60.2	85.6	91.0	103	117	141	172	180	189	196	196
Goodwill	391	431	579	598	733	728	843	822	873	973	981	975	975
Long-term debt including finance leases	73.0	91.5	344	339	493	344	329	243	350	319	346	200	200
Operating lease liabilities	n/a	n/a	n/a	n/a	0.0	67.2	67.6	58.1	93.8	87.6	84.0	74.2	74.2
Shareholders' equity	847	879	950	1,079	1,166	1,381	1,563	1,702	1,967	2,069	1,919	2,108	2,108
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	9.3%	5.5%	2.2%	-0.4%
Profit growth, compounded	5.7%	5.3%	-13.9%	147.7%
Return on equity, average	10.5%	10.2%	6.9%	8.6%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Biological Products, (No Diagnostic Substances)

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Amgen Inc. AMGN	$212.5 billion	24.44	74.8%	30.0%	9.1%	4.90	1.9%
Gilead Sciences, Inc. GILD	$186.8 billion	n/a	-27.4%	-8.2%	5.5%	2.22	2.1%
Moderna, Inc. MRNA	$69.0 billion	n/a	-46.6%	-149.0%	-27.6%	0.09	n/a
Biogen Inc. BIIB	$32.3 billion	23.56	7.4%	16.3%	1.2%	0.34	n/a
Bio-Techne Corp. TECH	$11.3 billion	62.47	8.6%	20.7%	-0.4%	0.09	0.4%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-K	30 June 2026	24 August 2026	EDGAR
10-Q	31 March 2026	6 May 2026	EDGAR
10-Q	31 December 2025	4 February 2026	EDGAR
10-Q	30 September 2025	5 November 2025	EDGAR
10-K	30 June 2025	22 August 2025	EDGAR
10-Q	31 March 2025	8 May 2025	EDGAR
10-Q	31 December 2024	6 February 2025	EDGAR
10-Q	30 September 2024	5 November 2024	EDGAR
10-K	30 June 2024	22 August 2024	EDGAR
10-Q	31 March 2024	6 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install